In murine CML models, abrogation of PD-1 expression increases overall survival [137, 138] suggesting that blocking the PD-1/PD-L1 pathway may represent a new therapeutic strategy for CML. This evidence concerns the gene CD274 and chronic myelogenous leukemia, BCR-ABL1 positive.